

Statement of Advice:

liraglutide (Saxenda®) 6mg/mL solution for injection in pre-filled pen **(No: 1247/17)**

Novo Nordisk Limited

07 April 2017

ADVICE: in the absence of a submission from the holder of the marketing authorisation

liraglutide (Saxenda®) is not recommended for use within NHS Scotland.

Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of

- $\geq 30\text{kg/m}^2$ (obese), or
- $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman,
Scottish Medicines Consortium**